Lineage Cell Therapeutics (LCTX) EBITDA Margin Growth (1y) (2011 - 2026)
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -1,651.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,091.00 |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | -11,933.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11,933.00 |
| Mar 31, 2026 | -708.00 |
| Dec 31, 2025 | 7,908.00 |
| Sep 30, 2025 | -124.00 |
| Jun 30, 2025 | -29,868.00 |
| Mar 31, 2025 | 2,820.00 |
| Dec 31, 2024 | 12,652.00 |
| Sep 30, 2024 | 43,651.00 |
| Jun 30, 2024 | -26,091.00 |
| Mar 31, 2024 | -18,291.00 |
| Dec 31, 2023 | 4,199.00 |
| Sep 30, 2023 | -36,297.00 |
| Jun 30, 2023 | -6,279.00 |
| Mar 31, 2023 | -15,624.00 |
| Dec 31, 2022 | -29,021.00 |
| Sep 30, 2022 | 12,630.00 |
| Jun 30, 2022 | 128,982.00 |
| Mar 31, 2022 | 168,094.00 |
| Dec 31, 2021 | 160,043.00 |
| Sep 30, 2021 | 87,630.00 |